Shaheer Khan, Sapna P Patel, Alexander N Shoushtari, Grazia Ambrosini, Serge Cremers, Shing Lee, Lauren Franks, Shahnaz Singh-Kandah, Susana Hernandez, Naomi Sender, Kristina Vuolo, Alexandra Nesson, Prabhjot Mundi, Benjamin Izar, Gary K Schwartz, Richard D Carvajal
Introduction: Uveal melanoma (UM) is associated with poor outcomes in the metastatic setting and harbors activating mutations resulting in upregulation of MAPK signaling in almost all cases. The efficacy of selumetinib, an oral allosteric inhibitor of MEK1/2, was limited when administered at a continual dosing schedule of 75 mg BID. Preclinical studies demonstrate that intermittent MEK inhibition reduces compensatory pathway activation and promotes T cell activation. We hypothesized that intermittent dosing of selumetinib would reduce toxicity, allow for the administration of increased doses, and achieve more complete pathway inhibition, thus resulting in improved antitumor activity...
2022: Frontiers in Oncology